SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and modestly raised its full-year outlook, but the stock is selling off to a new 52-week low. Traders are split between short sellers focused on weak revenue trends and competitive risks, and bulls who see the cash balance and buyback authorization as support for an undervalued business.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BATs sharp move higher is drawing attention as traders point to technical breakout momentum and a broader pickup in altcoins; no specific token-related catalyst is clearly confirmed. The community is largely bullish on continuation, while others warn about profit-taking and a possible pullback after the rally.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the expected Q4 Phase 3 topline readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that positive data could validate the program and concern about the binary trial risk, potential dilution, and recent weak price action.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,020,742,700.022444 with 95,020,750,177.733244 in circulation. The last known price of TRON is 0.3287714 USD and is down -6.58 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,904,975,878.16 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for a sharp decline and underperforming other altcoins that traders describe as green; bearish chart setups and talk of a corrective pullback contrast with holders viewing the weakness as a pause in its longer-term climb.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Natural gas weakness tied to mild-weather forecasts and ample storage is the dominant topic, with traders noting the price slide and looking for lower entry points. Some are buying dips in anticipation of winter cold or a sharp weather-driven rebound, while others remain bearish on warm-winter risk and persistent supply.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A quarterly earnings beat and higher full-year sales outlook, driven by demand for Mounjaro and Zepbound, have fueled LLYs advance to record highs. Traders are largely bullish on the growth, while some question the valuation and point to lower profit guidance from acquisition charges and weaker Foundayo sales amid competition in oral obesity drugs.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu is selling off alongside Brazilian equities after Lulas reelection prompted investors to reassess the countrys political and fiscal outlook; traders note the move appears macro-driven rather than tied to new company news. The community is divided between viewing the drop as an overreaction and buying opportunity and worrying about Nus heavy exposure to Brazil and the risks of its policy environment.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention for a sharp rebound and renewed buying momentum, with traders watching whether it can clear resistance and sustain a breakout. Bulls are accumulating and pointing to Chainlinks role in institutional tokenization and interoperability, while skeptics warn that the rally could fade and question whether network adoption translates into value for the token.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A reported major Binance security breach has fueled crypto-market concern and Bitcoin selling, weighing on Strategy as a Bitcoin proxy. Traders are split between viewing the selloff as a buying opportunity and warning of further downside; Q3 revenue concerns and the CFO transition add to the bearish debate.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is drawing attention amid a sharp selloff across data-center and AI-infrastructure stocks, as traders debate concerns about AI demand, project financing, execution risk, and higher yields. Bears see further downside and question the companys ability to turn its buildout into profits, while bulls call the decline an overreaction and point to long-term data-center demand and HUTs Bitcoin exposure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation 

Equity

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.


Legend Biotech Appoints Ingrid Zhang As CEO

(RTTNews) - Legend Biotech Corp. (LEGN), a cell therapy company, on Tuesday appointed Ingrid Zhang as Chief Executive Officer, effective September 15...

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus...

LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset 

Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24. 


Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress...

Why Is Legend Biotech Stock Falling Thursday?

Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.read more...

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.read more...

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Legend Biotech Corp - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Chairman Frank Zhang said the board picked Ingrid Zhang after a full search to guide Legend through its next phase of growth.</li><li>Legend’s commercial engine is CARVYKTI, a CAR-T cell therapy for multiple myeloma developed and sold with Johnson &amp; Johnson.</li><li>Retail is anticipating a buyout of Legend, with some speculating it would come from one of the company’s partners.</li></ul>Legend Biotech (LEGN) named Ingrid Zhang as chief executive on Tuesday, ending a two-month search that began when former CEO Ying Huang resigned in July and setting the stage to expand its offerings beyond CARVYKTI and paving the way for buyout speculation.The company said that the new CEO appointment is effective immediately. Alan Bash, who ran the company on an interim basis, will return to his job as president of CARVYKTI.Zhang most recently served as chief commercial officer for Novartis International. She also led Novartis’s China business and its innovative-medicines organization and spent earlier years at AstraZeneca, Pfizer, and McKinsey. Chairman Frank Zhang said the board picked her after a full search to guide Legend through its next phase of growth. Zhang said she wants to build on the company’s cell-therapy foundation, push the pipeline, and execute the long-term plan.<h2 class="st-heading-2">JNJ Partnership For CARVYKTI</h2>Legend’s commercial engine is CARVYKTI (ciltacabtagene autoleucel), a CAR-T cell therapy for multiple myeloma developed and sold with Johnson &amp; Johnson. The partners share costs and profits outside Greater China. CARVYKTI is now in 19 markets and about 348 treatment centers. Second-quarter net trade sales were about $657 million, up 50% from a year earlier. Full-year 2025 sales were about $1.9 billion, and first-half 2026 sales were about $1.25 billion. Legend is still trying to move the drug earlier in myeloma, with several studies studying the drug in newly diagnosed patients.<h2 class="st-heading-2">Novartis-Legend Partnership</h2>In November 2023, Legend licensed Novartis exclusive worldwide rights to DLL3-targeted CAR-T therapies, including LB2102, for small-cell lung cancer and related tumors. Novartis paid $100 million up front and could owe up to $1.01 billion in milestones, plus royalties.Legend ran the U.S. early-stage study for LB2102. Novartis is responsible for later development, manufacturing, and sales. Early LB2102 data showed responses in heavily pretreated patients; the program is now in follow-up.Beyond that, Legend is advancing LB1908 in gastric and pancreatic cancers, LB2401 in myeloma, and an in vivo CAR-T program, LB2501, with an investigational new drug filing expected in the second half of 2026.<h2 class="st-heading-2">How Did LEGN Retail Traders React?</h2>On Stocktwits, retail sentiment around LEGN stock shifted from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.A Stocktwits user expressed optimism about Novartis buying Legend.<stembedurl>https://stocktwits.com/KY3000/message/664330468</stembedurl>Another user applauded the new CEO appointment, saying it might allow the company to put favorable pressure on its other partner, Johnson. “A blockbuster drug and a very promising pipeline will ultimately reward investors,” they added.<stembedurl>https://stocktwits.com/Stockseeking/message/664324550</stembedurl>A third user opined that the stock is undervalued at current levels.<stembedurl>https://stocktwits.com/mulc/message/664318036</stembedurl><a href="https://stocktwits.com/symbol/LEGN">LEGN stock</a> has fallen 19% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/iova-flags-year-end-data-slate-after-record-amtagvi-quarter-highlights-clear-line-of-sight-to-profitability/cZtnpgQRBcy">IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation

Johnson & Johnson

Legend Biotech

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$21.63
Prev Close	$22.30
Open	$22.12
Dividend Yield	0.00%
50-Day Moving Average	$19.55
Beta	0.55
Avg. Volume	2.22M
PE Ratio	-43.35

52-Week High	$37.50
52-Week Low	$16.24
Market Capitalization	$4.19B
EPS (Annual)	-$1.61
Price to Book	3.41
Revenue Per Employee	$355,731.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

LEGN Fundamentals